VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, November 8, 2023.
Conference Call/Webcast Information:
| Date: | Wednesday, November 8, 2023 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-In: | (800) 715-9871 or (646) 307-1963 for international callers |
| Conference ID: | 4249948 |
A live audio webcast will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$31.42 |
| Daily Change: | -0.41 -1.29 |
| Daily Volume: | 846,892 |
| Market Cap: | US$2.410B |
June 03, 2025 May 14, 2025 May 12, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
